Eurosport 1

Captain Planet Foundation Raises More Than $800,000 at Annual Gala Honoring Environmental Heroes Josh Bernstein and Oluwaseyi Moejoh

Retrieved on: 
Sunday, March 17, 2024
Cox Media Group, Lindblad, History, Genuine Parts Company, Into, Georgia Aquarium, Gala, NFL, Corporate responsibility, HRH, The Coca-Cola Company, NASA, Eurosport 1, Chef, Climate change, Knowledge, Cat, Superhero, Student, STEM, Discovery, Francis Ford, Environment, Cox Enterprises, School, Social impact, Environmental justice, Atlanta Gas Light, Ray, Day, Unknown, Delta Air Lines

ATLANTA, March 17, 2024 (GLOBE NEWSWIRE) -- Last night, Captain Planet Foundation, the global non-profit, held their annual Gala at Flourish Atlanta and recognized environmental heroes, Josh Bernstein and Oluwaseyi Moejoh. Additionally, Cox Enterprises received the Corporate Superhero for the Earth Award. The benefit raised more than $800,000 to support the Foundation’s worldwide educational programming and grant-making efforts to engage and empower young people to be problem solvers for the planet. The Gala was hosted by Atlanta Journal-Constitution’s The Monica Pearson Show host, Monica Kaufman Pearson.

Key Points: 
  • ATLANTA, March 17, 2024 (GLOBE NEWSWIRE) -- Last night, Captain Planet Foundation , the global non-profit, held their annual Gala at Flourish Atlanta and recognized environmental heroes, Josh Bernstein and Oluwaseyi Moejoh.
  • The Gala was hosted by Atlanta Journal-Constitution’s The Monica Pearson Show host, Monica Kaufman Pearson.
  • More than 400 guests were in attendance to celebrate the honorees and the impact that Captain Planet Foundation has had on youth around the world.
  • Captain Planet Foundation also introduced the Laura Turner Seydel Legacy Fund which will support the Planeteer Alliance, additional scholarships, and programing for the Foundation.

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

Salipro Biotech Obtains Grant for Key Patent from the European Patent Office

Retrieved on: 
Thursday, March 14, 2024
Eurosport 1, Drug discovery, Business, EPO, G protein-coupled receptor, IP, European Patent Convention, Patent, Therapy, Pharmaceutical industry

STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'. This patent covers processes related to the Salipro® platform and represents a pivotal milestone that strengthens Salipro Biotech's position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.

Key Points: 
  • This additional European patent will further strengthen Salipro Biotech's integrated IP portfolio protecting its proprietary Salipro® platform technology to stabilize challenging drug targets and enable the discovery and development of next-generation therapeutics.
  • STOCKHOLM, March 14, 2024 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, today announced that the European Patent Office (EPO) has granted a further patent in Salipro Biotech's growing patent portfolio: European Patent EP 3 955 895 B1, entitled 'Production of Salipro® particles'.
  • This patent is based on one of multiple patent filings of Salipro Biotech since 2016.
  • The grant of the European patent will provide Salipro Biotech's unique platform technology with a broader protection, further strengthening its patent portfolio to address unmet medical needs and accelerate drug discovery programs against undruggable targets.

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Retrieved on: 
Wednesday, February 21, 2024
Immunization, G protein-coupled receptor, Drug discovery, ADC, Antibody, Eurosport 1, Protein, Cancer, Vaccine

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Key Points: 
  • ActivMAb’s new “Antigen Virus” application is a powerful complement to drug discovery strategies targeting complex protein targets including ion channels and G-protein coupled receptors (GPCRs) such as chemokine receptors.
  • We believe that this is a much more highly purified presentation and efficient selection technology than the complex natural membrane fragments that have been termed virus-like particles.
  • “We have recently publicized success in selecting high value antibodies against challenging multi-pass membrane targets.
  • We are excited to be able to capitalize on what we believe is recognition of the unique capabilities of our drug discovery technology.

Fujifilm Celebrates Recent Recipients of Fujifilm Fellowships at Harvard Medical School

Retrieved on: 
Tuesday, February 20, 2024
Lilium, Therapy, Research, Doctor of Philosophy, Drug resistance, Chemical biology, G protein-coupled receptor, Biology, Obesity, Pain, MIT, Harvard University, Drug discovery, Eurosport 1, Health, Fujifilm, Faculty (division), Disease, Massachusetts General Hospital, Harvard Medical School, Infection, Publication, Faculty, Fujifilm Diosynth Biotechnologies, Management

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today announced the nine most recent Fujifilm Fellows at Harvard Medical School.
  • These PhD students from around the world are part of the Harvard Medical School Therapeutics Graduate Program working to advance therapeutics discovery, development, and applications to improve the treatment of disease.
  • Launched with six fellows in 2019, the Fujifilm Fellowship has now grown to reach 34 recipients to date, including six alumni.
  • “Fujifilm is proud to support Harvard Medical School as it helps to shape our world’s future scientists.

Cunard Announces Royal Canadian Geographical Society Speaker Line-up for 2024 Alaska Season

Retrieved on: 
Monday, February 12, 2024
Soyuz, Astronaut, Eurosport 1, RCGS, Guinness World Records, Travel, NASA, Kenton Cool, MBE, Culture, Beauty, Weather, Nature, Discovery, Business development, Wilderness, Elephant, Royal Canadian Geographical Society, Royal, World Elephant Day, The Weather Network, Ice Road Truckers, Space Shuttle, OneSource, Exploration, Book, Russell Potter, Partnership, Tourism

VALENCIA, Calif., Feb. 12, 2024 /PRNewswire/ -- Cunard is proud to continue their partnership with the Royal Canadian Geographical Society and announces an extensive speaker line-up for the Alaska 2024 season, showcasing an RCGS speaker on every Alaska voyage starting June 21.

Key Points: 
  • VALENCIA, Calif., Feb. 12, 2024 /PRNewswire/ -- Cunard is proud to continue their partnership with the Royal Canadian Geographical Society and announces an extensive speaker line-up for the Alaska 2024 season, showcasing an RCGS speaker on every Alaska voyage starting June 21.
  • Experts from the Royal Canadian Geographical Society, one of Canada's largest non-profit geographical and educational organizations, will be featured on 2024 voyages from June to September.
  • RCGS speakers include celebrated and accomplished explorers, naturalists, geographical experts, astronauts, and indigenous advocates who will custom-curate exclusive programming for Cunard guests.
  • For Travel Advisors interested in further information, please contact your Business Development Manager, visit OneSource Cruises.com or call Cunard at 1-800-528-6273.

Cardinal Health to acquire Specialty Networks and its PPS Analytics platform, a technology enabled multi-specialty group purchasing and practice enhancement organization in urology, rheumatology and gastroenterology

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Practice management, EMR, Growth, Research, Cardinal Health, Natural language processing, Patient, Medication, Cardinal, Artificial intelligence, Physician, GPO, CAH, Acquisition, Eurosport 1, Nursing

Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.

Key Points: 
  • Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
  • "Expanding in specialty is a top priority for us and we have been investing to expand our offering," said Jason Hollar, CEO Cardinal Health.
  • "Specialty Networks is a leader in specialty practice management, research and technologies that support physicians in delivering best-in-class care to their patients," said Debbie Weitzman, CEO, Cardinal Health Pharmaceutical and Specialty Solutions.
  • Through its Specialty business, Cardinal Health provides reliable distribution and advanced technology solutions to community-based practices across the nation.

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

Retrieved on: 
Tuesday, January 30, 2024
Patient, D. E. Shaw Research, Simulation, Atopic dermatitis, Membrane, UC, Lilly, DESRES, RNA, Robots in Disguise, PPI, IBD, AI, Microsoft Dynamics 365, Algorithm, DMPK, Eli Lilly and Company, Drug development, GPX4, Antibody, Prevalence, Intrinsically disordered proteins, Calcineurin, Eurosport 1, KCNA3, Internally displaced person, Conditional sentence, TH1, Drug discovery, Inflammatory bowel disease, Vaccine

The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.

Key Points: 
  • The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD.
  • Inhibition of Kv1.3 therefore offers a potential opportunity to specifically impair inflammatory immune cell activity and proliferation, including in antigen-activated T cells.
  • Long-lived memory T-cell populations, particularly tissue resident subsets, may contribute to the chronicity of IBD and represent a potential target for therapy[4].
  • It has shown positive results in preclinical animal models of various autoimmune diseases such as IBD and AD.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.